Bio-Techne has announced an agreement with Thermo Fisher Scientific to exclusively complete the development of and commercialise the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand, a press release claims.
ExoTRU is a non-invasive, multigene, urine-based liquid biopsy assay that provides critical allograft health information to assist clinician decision-making in managing kidney transplant patients and optimising patient care. The assay has the potential to discriminate between T-cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR), which is critical to improving patient management and outcomes.
ExoTRU was developed in collaboration with the Azzi Laboratory at the Transplantation Research Center at Brigham and Women’s Hospital, Harvard Medical School (Boston, USA).
“We continue to demonstrate the utility of exosomes as a source of significant clinical value for non-invasive testing. ExoTRU is another great example of this potential, with this assay filling a significant unmet need in the area of kidney transplant patient care,” commented Kim Kelderman, president of Bio-Techne’s diagnostics and genomics segment. “Thermo Fisher is the ideal partner to complete development of and commercialise ExoTRU, with its trusted reputation and established transplant centre relationships creating the ideal channel to drive awareness and adoption of this best-in-class assay.”
